

MONOCLONAL ANTIBODIES TO GLYCOPOLYPEPTIDES HA₁ AND HA₂ OF INFLUENZA VIRUS HAEMAGGLUTININ

G. RUSS, K. POLÁKOVÁ*, F. KOSTOLANSKÝ, B. STYK, M. VANČÍKOVÁ

Institute of Virology, Slovak Academy of Sciences, 817 03 Bratislava, and *Cancer
Research Institute, Slovak Academy of Sciences, 812 32 Bratislava,
Czechoslovakia

Received December 6, 1986

Summary. — Anti-haemagglutinin monoclonal antibodies were prepared and their HA₁ or HA₂ specificity was determined by solid phase radioimmunoassay (RIA) using purified viral haemagglutinin (HA) and haemagglutinin glycopolypeptides HA₁ and HA₂, by radioimmunoprecipitation followed with SDS-PAGE, by immunoblotting and by inhibition of virus-induced haemagglutination. The capacity of these methods to estimate HA₁ or HA₂ specificity of anti-HA monoclonal antibodies (MoAb) was compared. HA₁ specificity was demonstrated for all hybridomas originating from lymphocytes of mice immunized with complete influenza virus, except IIF4 hybridoma which was HA₂-specific. All hybridomas obtained with lymphocytes from mice immunized with HA glycopolypeptide HA₂ were HA₂-specific. Anti-HA₂ MoAb neither inhibit haemagglutination induced by the virus or by HA subunits nor neutralized viral infectivity, either alone or in mixture. As expected, all anti-HA₁ MoAb were H3 subtype-specific, showing usually good reactivity only with viruses close to the virus strain used for immunization. Two anti-HA₁ MoAb (IVA1 and IVG6) showed unusual cross-reactivity within the H3 subtype. All anti-HA₂ MoAb were broadly cross-reactive within the H3 subtype. Moreover, a half of them showed high cross-reactivity with influenza viruses of the H7 HA subtype. But the same antibodies did not react with HA of H1, H2 and H8 subtypes.

Key words: Influenza virus; haemagglutinin glycopolypeptides HA₁ and HA₂; monoclonal antibody

Introduction

The haemagglutinin (HA) is the major glycoprotein of influenza virus, it mediates virus adsorption and penetration into host cells and is important for the induction of protective immunity. HA exist in the form of spikes composed of three identical monomers, each consisting of a glycopolypeptide HA₁ and a glycopolypeptide HA₂ joined by a single disulphide bond (for review see Ward, 1981).

Anti-HA antibodies neutralizing virus and inhibiting haemagglutination are directed primarily toward HA₁ (so far, no exception from this rule has been well documented). Four dominant antigenic regions have been defined on the globular head of the molecule formed by this glycopolypeptide (Wiley *et al.*, 1981; Caton *et al.*, 1982).

Studies on the antibody-binding sites of HA have been focused primarily on determinants of the HA₁ glycopolypeptide. Therefore, much less is known about the antigenic properties of the HA₂ subunit of HA which together with a part of HA₁ forms the fibrous stalk region that anchors the HA molecule into the envelope (Wilson *et al.*, 1981).

Early studies suggested that the HA₂ subunit does not contribute significantly to the antigenic structure of HA in the intact virus (Brand and Skehel, 1972; Eckert, 1972; Schild *et al.*, 1976; Kuo *et al.*, 1976). In rabbit sera produced against intact virus or purified undissociated HA (Russ *et al.*, 1978) and, more important, also in human convalescent sera (Styk *et al.*, 1979) we demonstrated antibodies by gel double immunodiffusion and RIA reactive with both influenza HA subunits (HA₁ and HA₂). Moreover, we obtained direct evidence of the immunogenicity of the isolated HA glycopolypeptides HA₁ and HA₂ in rabbits (Styk *et al.*, 1979). It was later confirmed that the animal sera raised to intact influenza A virus preparations or subviral particles exposed to pH 5.0 and lacking the HA₁ subunit contained both HA₁- and HA₂-specific antibodies (Brown *et al.*, 1980; Graves *et al.*, 1983).

Since the HA₂ region of the HA molecule is highly conserved among all influenza A viruses, it was not surprising that, at least in some cases, inter-subtype cross-reactivity with HA₂-specific antibodies was demonstrated (Russ *et al.*, 1978; Graves *et al.*, 1983).

The recognition of influenza virus HA by T cells was shown to involve recognition of determinants on both the HA₁ (Lamb *et al.*, 1982; Hurwitz *et al.*, 1984; Katz *et al.*, 1985a) and HA₂ glycopolypeptides (Wabuke-Bunoti and Fan, 1983; Katz *et al.*, 1985b). HA₂ with its conserved regions could be a target antigen for some T cells, particularly for cytotoxic T cells showing an unusually high degree of cross-reactivity (Wabuke-Bunoti and Fan, 1983; Katz *et al.*, 1985b; Kozinowski *et al.*, 1980; Askonas *et al.*, 1980; Anders *et al.*, 1981; Lamb *et al.*, 1982; Braciale, 1984; Fleischer *et al.*, 1985).

Recently, the first panel of anti-HA₂ monoclonal antibodies was used to study the immunogenic properties of HA₂. These monoclonal antibodies were, however, subtype-specific, and no positive results concerning the role of HA₂ in humoral or cell-mediated immunity to influenza have been obtained (Becht *et al.*, 1984).

In the present report we describe the preparation and characterization of MoAb specific to either HA₁ or HA₂ glycopolypeptide.

Materials and Methods

Viruses. The following influenza virus strains and recombinants were used: A/Dunedin/4/73 (H3N2) which will be referred to as strain "Dun"; A/Bangkok/1/79 (H3N2) — "Bang"; A/Hong Kong/1/68 (H3N2) — "HK"; A/Belgium/2/81 (H3N2) — "Belg"; A/Caen/1/84 (H3N2) — "Caen";

A/England/403/80 (H1N1) — "Eng"; A/PR/8/34 (H1N1) — "PR8"; A/Singapore/1/57 (H2N2) — "Sing"; A/Ty/Ont/61/68 (H8N4) — "Ont"; B/Hong Kong/8/73 — "B/HK"; X-42 (H7N2) — "X-42"; X-38 (H7N2) — "X-38"; and X-53 (H1N1) — "X-53". The conditions for infection of embryonated hen's eggs and the mode of purification of the viruses have been described (Styk and Blašković, 1973; Russ *et al.*, 1974).

Isolation of bromelain purified HA (BHA), glycopolypeptides BHA₁ and BHA₂, and iodination procedures were described previously (Poláková *et al.*, 1978). Glycopeptides were prepared by pronase digestion of the purified BHA₂.

Preparations of hybridoma cell lines. Hybridoma cell lines were prepared by fusion of mouse myeloma cell line Sp2/0 with spleen cells from immunized BALB/c mice using polyethylene glycol according to established procedures (Gerhard, 1980). BALB/c mice, which had been primed by intraperitoneal (i.p.) injections of purified virus (100 µg), or BHA₂ (100 µg) in incomplete Freund's adjuvant, were challenged intravenously (i.v.) 3 days before fusion. After fusion, the cells were distributed into 96-well microtitre plates on a feeder of spleen cells. The feeder cells (10⁵/well) were seeded 24 hr before fusion and on the day of fusion they were irradiated with 20 Gy (⁶⁰Co, Chisobalt, Chirana, Prague). Cultures producing antibody to the influenza virus were cloned in soft agar. Hybridoma cell cultures were maintained in Dulbecco's modified Eagle's minimal essential medium containing foetal calf serum, 50 µg/ml gentamycine and 2 mmol/l glutamine at 37 °C in humidified atmosphere containing 5% CO₂. Ascitic fluids containing hybridoma antibodies were obtained from paraffine oil-primed BALB/c or DBA mice inoculated i.p. with approximately 5 × 10⁶ hybridoma cells each.

Solid phase radioimmunoassay (RIA). An indirect antibody-binding assay with ¹²⁵I-labelled rabbit anti-mouse F(ab')₂ (Poláková and Russ, 1983) was used for the initial screening of hybridomas as well as for further characterization of monoclonal antibodies.

Determination of Ig class and subclass. The isotypes of the monoclonal antibodies were determined by a double antibody RIA (Poláková and Russ, 1983).

Immunoprecipitation and SDS-PAGE. *S. aureus* was incubated first for 15 min with swine anti-mouse Ig serum and then washed 5 times with PBS containing 0.5% Triton-X-100. This pretreatment ensured precipitation of all mouse Ig isotypes. Then *S. aureus* loaded with anti-mouse Ig was added to ¹²⁵I-labelled BHA which had previously been incubated in the presence of 0.5% Triton-X-100 and 0.1% 2-mercaptoethanol with 5 µl of ascitic fluid. After 1 hr incubation *S. aureus* cells were pelleted and washed 5 times. Adsorbed proteins were eluted from *S. aureus* by boiling in SDS-PAGE sample buffer and the eluates were analysed on 10% polyacrylamide gels (Laemmli, 1970). The gel was dried for autoradiography, and autoradiographs were made with Medix Rapid X-ray film (Czechoslovakia), using intensifying screens at -70 °C.

Immunoblotting. Haemagglutinin glycopolypeptides from SDS-PAGE were electrophoretically transferred to nitrocellulose sheets (Millipore GSWP, 0.22 µm pore size). After incubation of immobilized proteins with MoAb, the immune complexes were detected by using anti-immunoglobulin conjugated to horseradish peroxidase followed by treatment with diaminobenzidine to localize the peroxidase.

Haemagglutination and haemagglutination inhibition (HI) titres were determined by a microtechnique as described (Russ *et al.*, 1978). HI titres were expressed per 0.025 ml as reciprocals of the highest initial dilution of antibody causing inhibition of 4 HA units of the homologous virus. A means for increasing the reactivity of MoAb in HI test was adding sheep anti-mouse Ig into the reaction mixture or detergent treatment of the virus used.

Results

HA₁ and HA₂ specificity of anti-HA monoclonal antibodies

The specificity of anti-HA MoAb to HA₁ or HA₂ glycopolypeptide was first examined in solid phase RIA. The results obtained are shown in Tables 1 and 2. Monoclonal antibodies IB8, IC8, IVA1 and IVG6 prepared against the strain Dun were clearly specific to the HA₁ glycopolypeptide. MoAb IB5 and IIC5 showed significant binding also to BHA₂, but the reactions with BHA₁ were preferential. We can conclude, therefore, that also these MoAb

Table 1. Reactivity of MoAb to HA₁ in solid-phase RIA

MoAb to HA ₁ (Dun.)	Parental virus	BHA (Dun.)	BHA ₁ (Dun.)	BHA ₂ (Dun.)	B/HK
IB5	4 098	4 592	8 610	2 091	287
IIC5	3 102	2 511	4 991	1 302	310
IB8	5 795	522	1 972	174	232
IC8	5 480	385	2 310	220	247
IVA1	3 398	1 394	3 298	204	204
IVG6	4 020	1 292	4 284	306	255
MoAb to HA ₁ (Bang.)					
IIB4	2 300	1 104	506	*N.D.	299
IIG3	1 502	300	300	N.D.	300
IIE5	3 085	510	390	N.D.	510
IIF5	3 022	390	388	N.D.	390

*N.D. — not done

The figures represent the radioactivity (cpm) bound in solid-phase RIA

were specific to the HA₁ glycopolypeptide. All six MoAb specific to the HA₁ glycopolypeptide mentioned above showed a higher binding to HA₁ than to HA and a lower binding to HA than to the whole virus (particularly MoAb IB8 and IC8). The results did not show fine specificity for the remaining MoAb, since HA from influenza virus A/Bangkok/1/79 (H3N2) was not available. The solid phase RIA with various virus strains and recombinants proved the HA specificity of anti-A/Bangkok MoAb (results not shown). Since all these MoAb were positive in the HI test (Table 3), they are considered as HA₁-specific and listed together with other HA₁-specific MoAb.

Table 2. Reactivity of MoAb to HA₂ in solid-phase RIA

MoAb to HA ₂ (Dun.)	Dunedin	BHA (Dun.)	BHA ₁ (Dun.)	BHA ₂ (Dun.)	*CHO
IIF4	3 400	2 108	2 312	1 496	205
BB8	2 946	3 991	1 119	3 730	596
CF2	1 606	3 062	125	2 510	75
EB12	2 361	3 715	432	2 880	201
FC12	1 386	2 980	554	2 310	346
FE1	530	2 917	326	2 040	142
CB8	2 650	4 610	1 016	3 630	363
EF1	662	1 060	770	1 040	391

*CHO — oligosaccharides obtained by pronase digestion of the HA₂ glycopolypeptide

Table 3. HI activity of MoAb to HA₁: standard conditions and potentiation with sheep anti-mouse Ig

MoAb to HA ₁	Parental virus	
	standard conditions	sheep anti-mouse Ig added
Dunedin		
IB5	<10	<10
IIC5	<10	<10
IB8	80-160	2 560
IC8	80-160	1 280
IVA1	<10	<10
IVG6	<10	<10
IVC4	<10	<10
Bangkok		
IIB4	> 2 560	> 2 560
IIG3	80-160	2 560
IIE5	80-160	2 560
IIF5	80-160	2 560

The titres are expressed per 0.025 ml as reciprocals of the highest dilution of antibody causing inhibition of 4-8 HAU of the respective virus

HA₁-specific MoAb were produced by hybridomas obtained by fusion of myeloma cells with splenocytes from mice immunized with influenza viruses A/Dunedin/4/73 (H3N2) (i.e. IB5, IIC5, IB8, IC8, IVA1, and IVG6) or A/Bangkok/1/79 (H3N2) (i.e. IIB4, IIG3, IIE5, and IIF5).

The results of solid phase RIA concerning MoAb specific to the HA₂ glycopolypeptide are summarized in Table 2. These MoAb showed preferential binding to BHA₂. The HA₂-specificity was evident particularly for the four MoAb CF2, EB12, FC12 and FE1. Nevertheless, the less clear reactivity pattern for the remaining MoAb of this group is also in agreement with their HA₂-specificity. These results revealed no glycopolypeptide specificity for IIF4 MoAb. Because HA₂-specificity of this MoAb was unambiguously proved by radioimmunoprecipitation and immunoblotting, we included the IIF4 MoAb into Table 2. Rather high binding of all anti HA₂ MoAb to HA indicates that either corresponding epitopes are accessible or they became accessible due to changes in BHA by adsorption to polystyrene microplate (see FE1, Table 2). It is noteworthy that for all MoAb listed in Table 2 their carbohydrate specificity was excluded not only by lack of reactivity with influenza virus B (results not shown) but also with glycopeptides obtained from purified BHA₂ by exhaustive pronase digestion. All anti-HA₂ specific MoAb, with the exception of the IIF4 MoAb, were produced by hybridomas obtained by fusion of myeloma cells with splenocytes from two mice immunized with purified BHA₂. MoAb IIF4 was produced by

Table 4. "Cross-reactivity" of MoAb to HA₁ in solid-phase RIA

MoAb to HA ₁	HK 68	Dun. 73	Bang. 79	Belg. 81	Caen. 85	B/Hk
IB5	1 681	4 100	205	*N.D.	N.D.	287
IIC5	1 085	3 120	310	N.D.	N.D.	310
IB8	1 102	5 795	174	N.D.	N.D.	232
IC8	1 105	5 492	220	N.D.	N.D.	247
IVA1	1 961	3 925	3 720	3 896	3 404	182
IVG6	2 503	5 045	4 396	4 442	4 085	256
IVC4	N.D.	5 322	3 402	3 762	2 946	342
IIB4	2 166	2 778	4 613	4 704	1 778	174
IIG3	N.D.	236	4 648	4 189	3 517	258
IIE5	N.D.	168	6 213	5 633	4 919	218
IIF5	N.D.	384	6 551	5 948	5 627	294

*N.D. — not done

The figures represent the radioactivity (cpm) bound in solid-phase RIA.

None of the MoAb given in this table reacted with the following influenza virus strains and recombinants: Eng. (H1), PR8 (H1), Sing. (H2), X-42, X-38, X-53, Ont.

a hybridoma obtained after fusion of myeloma cells with splenocytes from mice immunized with influenza virus A/Dunedin/4/73 (H3N2).

The specificity of the MoAb was further characterized in a radioimmuno-precipitation test employing ¹²⁵I-labelled BHA or virus. The precipitation was performed after incubation of BHA with MoAb under reducing conditions, which allowed dissociation of HA₁ and HA₂, either directly with *S. aureus* or after loading *S. aureus* with swine anti-mouse Ig. As expected, anti-HA₂ MoAb, with the exception of EF1 MoAb, precipitated preferentially the HA₂ chain (Figs. 1 and 2). But some anti-HA₁ MoAb (IB5, IIC5, IVA1, and IVG6) precipitated equally both chains — HA₁ and HA₂ (Fig. 1). The remaining anti-HA₁ MoAb IIB4, IB8, and IC8 and anti-HA₂ MoAb EF1 did not precipitate any labelled antigen under the experimental conditions employed.

Table 5. "Cross-reactivity" of MoAb to HA₂ in solid-phase RIA

MoAb to HA ₂	HK	Dun.	Bang.	Belg.	X-42	Caen	B/HK
IIF4	3 100	4 579	3 682	3 376	204	2 942	488
BB8	4 902	5 029	4 402	4 466	2 761	4 687	969
CF2	2 019	2 584	2 215	2 345	1 430	2 223	112
EB12	3 899	4 441	4 309	4 108	2 131	4 019	714
FC12	2 916	3 431	3 318	3 199	415	2 154	540
FE1	1 574	2 059	1 329	1 257	286	783	342
CB8	3 326	3 794	3 295	3 252	1 960	3 274	608
EF1	1 066	1 184	1 146	1 096	610	1 101	628

The figures represent the radioactivity (cpm) bound in solid-phase RIA.

Table 6. Data summarizing the fine specificity of MoAb to HA

MoAb	SP-RIA	RIP	Blot	HI-VN	Isotype
IB5	HA ₁ (?)	HA ₁ + HA ₂	HA ₁	—	IgG2a
IIC5	HA ₁ (?)	HA ₁ + HA ₂	HA ₁	—	IgG3
IB8	HA ₁	neg.	neg.	+	IgG2a
IC8	HA ₁	neg.	neg.	+	IgG2a
IVA1	HA ₁	HA ₁ + HA ₂	HA ₁	—	IgG2a
IVG6	HA ₁	HA ₁ + HA ₂	HA ₁	—	IgG1
IVC4	N.D.	N.D.	HA ₁	—	
IIB4	N.D.	neg.	neg.	+	IgG2a
IIG3	N.D.	N.D.	neg.	+	IgG1
IIE5	N.D.	N.D.	neg.	+	IgG2a
IIF5	N.D.	N.D.	neg.	+	IgG2a
IIF4	HA ₂ (?)	HA ₂	HA ₂	—	IgG1
BB8	HA ₂ (?)	HA ₂	HA ₂	—	IgG1
CF2	HA ₂	HA ₂	neg.	—	IgG1
EB12	HA ₂	HA ₂	HA ₂	—	IgG1
FC12	HA ₂	HA ₂	HA ₂	—	IgG1
FE1	HA ₂	HA ₂	HA ₂	—	IgG2a
CB8	HA ₂ (?)	HA ₂	HA ₂	—	IgG1
EF1	HA ₂ (?)	neg.	(HA ₂)	—	IgM

N.D. — not done

parentheses indicate low reactivity

+ and — means positive or negative in HI and VN tests respectively

? means that the results of SP RIA were ambiguous

Finally, the specificity of the MoAb was analysed by immunoblotting. Figs. 3 and 4 shows the results obtained. Immunoblotting thus confirmed the HA₂-specificity of the IIF4, BB8, EB12, FC12, FE1, CB8, and EF1 MoAb. The remaining six anti-HA₁ MoAb (IB8, IC8, IIB4, IIG3, IIE5, IIF5) and one anti-HA₂ MoAb (CF2) did not react with immobilized proteins. The same MoAb, with the exception of CF2 MoAb, were negative in both radioimmunoprecipitation and immunoblotting.

The capacity of anti-HA₁ and anti-HA₂ monoclonal antibodies to inhibit haemagglutination and to neutralize virus

In HI tests, anti-HA₁ MoAb IB8, IC8, IIB4, IIG3, IIE5, and IIF5 showed anti-haemagglutination activity, but high anti-HA titres were detected only with IIB4 MoAb (Table 3). We found that low anti-HA titres increased either by adding sheep anti-mouse Ig into the HI test system (Table 3) or by using this test with HA subunits instead of intact virus (results not shown). These modifications, however, failed to potentiate the eventual low HI activity of those MoAb, which were negative under standard conditions.

All anti-HA₂ MoAb were negative in the HI test under standard conditions and with sheep anti-mouse Ig. Moreover, they were all negative also in the

HI test with HA subunits solubilized from virus with either Triton-X-100 or deoxycholate, sarcosyl, or octylglucoside.

The VN capacity of anti-HA₁ MoAb correlated exactly with the results of the HI test, i.e. only MoAb positive in the HI test had a virus neutralizing capacity. Anti-HA₂ MoAb, either alone or in complete mixture, did not neutralize the virus infectivity.

Cross-reactivity of anti-HA₁ and anti-HA₂ monoclonal antibodies

Variation within the HA₁ subunit is higher than in the HA₂ subunit. Accordingly, we found that anti-HA₂ MoAb were more cross-reactive than anti-HA₁-specific antibodies. All anti-HA₂ antibodies were fully cross-reactive within the H3 subtype; moreover, a half of them cross-reacted with the H7 subtype (Table 5). No cross-reactivity was detected with HA of H1, H2, and H8 subtypes (results not shown); further HA subtypes were not tested.

By contrast, all anti-HA₁ antibodies were H3 subtype-specific and they usually showed a good reactivity only with strains close to the parental virus (i.e. virus used for immunization and selection of hybridomas). Nevertheless, MoAb IVA1 and IVG6, specific to HA₁, showed a remarkable cross-reactivity within the H3 subtype. These MoAb reacted with influenza viruses isolated in the period from 1968 to 1985 (Table 4).

Discussion

The purpose of our work was to prepare anti-haemagglutinin MoAb and to determine their specificity to HA glycopolypeptides HA₁ and HA₂. We have analysed this fine specificity of anti-HA MoAb by solid phase RIA (using purified HA and HA glycopolypeptides HA₁ and HA₂), radioimmuno-precipitation with SDS-PAGE and immunoblotting. Furthermore we considered the ability of MoAb to inhibit virus induced haemagglutination as a good evidence for its HA₁ specificity. This assumption inferred logically from the knowledge of the three-dimensional structure of influenza virus HA and from the failure of all anti-HA₂ MoAb, either those presented by us or those described by Becht *et al.* (1984), to inhibit virus-mediated haemagglutination.

The data on fine specificity of anti-HA MoAb obtained by different analyses are compared in Table 6. Solid phase RIA used in the present report should have provided a rapid, sensitive technique for distinguishing between antibodies directed against the HA₁ or HA₂ subunit. The results obtained, however, often did not clearly reveal the fine specificity of anti-HA MoAb (e.g. IIF4, CB8). A disadvantage of this otherwise simple method is that highly purified HA and HA glycopolypeptides HA₁ and HA₂ are required. In spite of that solid phase RIA proved to be very useful, because, when the HA and HA glycopolypeptides HA₁ and HA₂ were available, it revealed the HA₁ specificity of MoAb capable to inhibit virus-induced haemagglutination (i.e. IB8, IC8).

All anti-HA MoAb negative in the HI test gave immunoprecipitation and

yielded two different radioimmunoprecipitation patterns: (1) equal precipitation of both HA subunits, HA₁ and HA₂; and (2) preferential precipitation of the HA₂ chain. Coprecipitation of HA₁ and HA₂ due to the disulphide bond (joining HA₁ and HA₂ in the HA) could be excluded, because radioimmunoprecipitation was carried out under reducing conditions which ensured dissociation of HA₁ and HA₂ glycopolypeptides. We, therefore, explain these results by high hydrophobicity of the glycopeptide HA₂ (Poláková *et al.*, 1978). Most of the HA₂ molecules are present in the immunoprecipitation mixture as large aggregates containing few entrapped HA₁ molecules. Monoclonal antibody directed against an epitope on HA₁ almost completely precipitates also HA₂ molecules (precipitation pattern 1). In contrast, anti HA₂ MoAb precipitated preferentially the HA₂ subunit, because most of the HA₁ molecules exist in the reaction mixture in a monomeric form and thus cannot contaminate the HA₂ precipitate. This explanation was verified by immunoblotting, i.e. under conditions, under which such aggregates cannot be formed. With the exception of MoAb CF2, monoclonal antibodies negative in the HI test showed good reactivity also in immunoblotting. Anti-HA MoAb bound either to immobilized HA₁ (anti-HA₁) or HA₂ (anti-HA₂). No anti-HA MoAb was found which would bind to both immobilized HA glycopolypeptides, HA₁ and HA₂.

All examined anti-HA MoAb with the capacity to inhibit virus-induced haemagglutination were negative in both radioimmunoprecipitation and immunoblotting. These MoAb are apparently directed against discontinuous (conformational) epitopes, which were destroyed during radioimmunoprecipitation and immunoblotting under the experimental conditions used.

HA₁ specificity was demonstrated for all hybridomas originating from lymphocytes of mice immunized with complete virus, except IIF4 hybridoma, which was proved to be HA₂-specific. There is no problem to obtain anti-HA₂ polyclonal antibodies after immunization with complete virus or purified undissociated HA (Russ *et al.*, 1978). Such antibodies are present also in human and avian convalescent sera (Styk *et al.*, 1979; Becht *et al.*, 1984). Nevertheless, we confirmed here previous experience (Russ and Gerhard, unpublished results) that hybridomas with HA₂ specificity are rare or absent at all after using splenocytes from mouse immunized with complete virus for construction of hybridomas. The appearance of the IIF4 hybridoma might be accidental and not related to the immunization procedure at all. At present, we are unable to explain the phenomenon described above. Further anti-HA hybridomas were prepared by fusion of mouse myeloma cells with lymphocytes from mice immunized with purified HA glycopolypeptide HA₂. As expected, HA₂ specificity was demonstrated for all these hybridomas.

Anti-HA₁ monoclonal antibodies revealed high, low or no capacity to inhibit haemagglutination and to neutralize virus. We were able to increase low antihaemagglutinin titres either by adding sheep anti-mouse Ig into the HI test or by using HA subunits instead of intact virus in this test. A similar approach for increasing the reactivity of antibodies in the HI test has been described for many influenza viruses (Lu *et al.*, 1982; Kendal and Cate, 1983). But none of the modifications tested did potentiate an eventual low HI

activity of those MoAb which were negative under standard conditions. All anti-HA₂ MoAb were negative in HI tests under standard conditions, with sheep anti-mouse Ig and with HA subunits. We cannot explain why anti-HA₂ MoAb prepared by Becht *et al.* (1984) did inhibit haemagglutination of isolated HA and our MoAb did not. Anti-HA₂ MoAb, either each alone or in a mixture, did not neutralize virus infectivity.

When HA sequences for different HA subtypes were compared, little sequence homology was found within the HA₁ portion of the genes, while there was a significant homology between the HA₂ subunits (Krystal *et al.*, 1982). Since the region is highly conserved among all influenza A and B virus strains, it could provide a basis for eliciting inter-subtype cross-reactive antibodies. We described that rabbit antisera produced against intact virus of purified undissociated HA contained antibodies reactive with both HA glycopolypeptides HA₁ and HA₂, and that antibodies to the later showed inter-subtype cross-reactivity (Russ *et al.*, 1978). Graves *et al.* (1983) confirmed that anti-HA₂ specific antisera were cross-reactive with the HA₂ of an influenza A virus of a different subtype. Others found only subtype-specific anti-HA₂ antibodies (Brown *et al.*, 1980; Becht *et al.*, 1984). We found that HA₂ MoAb were more cross-reactive than HA₁-specific MoAb. All anti-HA₂ MoAb showed good reactivity with all examined strains of the H3 subtype, isolated from 1968 to 1985. Moreover, a half of them showed also inter-subtype cross-reactivity with the H7 subtype. This is in good agreement with the fact that H3 is even more related to the avian H7 than to other human HA subtypes (Air *et al.*, 1981; Saitov and Nei, 1986). Three out of four MoAb that cross-reacted with H7 subtype are directed against a single antigenic site (Russ *et al.*, 1987). It will be important to determine whether these MoAb are cross-reactive with other related subtypes, as H4 and H10. (Anti-HA₂ MoAb described by Becht *et al.* (1984) were subtype-specific.)

All anti-HA₁ MoAb were subtype-specific and usually showed good reactivity only with viruses close to the virus used for immunization and selection of hybridomas. MoAb IVA1 and IVG6 are in this respect of particular interest. As anti-HA₁-specific antibodies they showed unusual cross-reactivity within the H3 subtype (see Both *et al.*, 1983).

The present, anti-HA₂ MoAb are of particular interest. Their availability made it possible to determine the four independent antibody binding sites on the HA₂ glycopolypeptide (Russ *et al.*, 1988), and to show that changes in the antigenicity of the HA molecule at acidic pH involve both HA glycopolypeptides, HA₁ and HA₂ (Kostolanský *et al.*, 1988). Experiments are in progress to show whether epitopes corresponding to these MoAb are present on the surface of infected cells and to find out whether these MoAb recognize amantadine resistant mutants (Daniels *et al.*, 1985).

Acknowledgements. We thank Dr. W. Gerhard for his generous gift of the affinity-purified rabbit anti-mouse F(ab')₂, affinity-purified goat anti-rabbit Ig and for subclass-specific rabbit anti-mouse reagents. We are grateful to Dr. V. Valenta for the help in preparation of the manuscript. We also thank Mr. P. Kvičala, Mrs. J. Dudíková, Mrs. M. Valentínová and Mrs. D. Pečúchová for their help and technical assistance.

References

- Air, G. M., Blok, J., and Hall, R. M. (1981): Sequence relationships in influenza viruses, pp. 225–239. In D. H. L. Bishop and R. W. Compans (Eds): *The Replication of Negative Strand Viruses*, Elsevier North-Holland, New York.
- Anders, E. M., Katz, J. M., Jackson, D. C., and White, D. O. (1981): In vitro antibody response to influenza virus: Specificity of helper T cells recognizing hemagglutinin. *J. Immunol.* **127**, 669–672.
- Askonas, B. A., and Webster, R. G. (1981): Monoclonal antibodies to hemagglutinin and to H-2 inhibit the cross-reactive T cell populations induced by influenza. *Eur. J. Immunol.* **10**, 151–156.
- Becht, H., Huang, R. T. C., Fleischer, B., Boschek, C. B., and Rott, R. (1984): Immunogenic properties of the small chain HA₂ of the hemagglutinin of influenza viruses. *J. gen. Virol.* **65**, 173–183.
- Both, G. W., Sleight, M. J., Cox, N. J., and Kendal, A. P. (1983): Antigenic drift in influenza virus H3 hemagglutinin from 1968 to 1980: Multiple evolutionary pathways and sequential amino acid changes at key antigenic sites. *J. Virol.* **48**, 52–60.
- Braciale, T. J., Braciale, V. L., Henkel, T. J., Sambrook, J., and Gething, M. -J. (1984): Cytotoxic T lymphocyte recognition of the influenza hemagglutinin gene product expressed by DNA-mediated gene transfer. *J. exp. Med.* **159**, 341–354.
- Brand, C. M., and Skehel, J. J. (1972): Crystalline antigen from the influenza virus envelope. *Nature (Lond.)* **238**, 145–147.
- Brown, L. E., Dopheide, T. A. A., Ward, C. W., White, D. O., and Jackson, D. C. (1980): Antigenic determinants of influenza virus hemagglutinin. V. Antigenicity of the HA₂ chain. *J. Immunol.* **125**, 1583–1588.
- Caton, A. J., Brownlee, G. G., Yewdell, J. W., and Gerhard, W. (1982): The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 Subtype). *Cell* **31**, 417–427.
- Daniels, R. S., Downie, J. C., Hay, A. J., Knossow, M., Skehel, J. J., Wang, M. L., and Wiley, D. C. (1985): Fusion mutants of the influenza virus hemagglutinin glycoprotein. *Cell* **40**, 431–439.
- Eckert, E. A. (1973): Properties of an antigenic glycoprotein isolated from influenza virus hemagglutinin. *J. Virol.* **11**, 183–192.
- Fleischer, B., Becht, H., and Rott, R. (1985): Recognition of viral antigens by human influenza A virus-specific T lymphocyte clones. *J. Immunol.* **135**, 2800–2804.
- Gerhard, W. (1980): Fusion of cells in suspension and outgrowth of hybrids in conditioned medium, p. 370. In R. H. Kennett, T. J. McKearn, K. B. Bechtol (Eds): *Monoclonal Antibodies. Hybridomas: A new Dimension in Biological Analyses*. Plenum Press, New York.
- Graves, P. N., Schulman, J. L., Young, J. F., and Palese, P. (1983): Preparation of influenza virus subviral particles lacking the HA₁ subunit of haemagglutinin: Unmasking of cross-reactive HA₂ determinants. *Virology* **126**, 106–116.
- Hurwitz, J. L., Heber-Katz, E., Hackett, C. J., and Gerhard, W. (1984): Characterization of the murine T_H response to influenza virus hemagglutinin: Evidence for three major specificities. *J. Immunol.* **133**, 3371–3377.
- Katz, J. M., Laver, W. G., White, D. O., and Anders, E. M. (1985a): Recognition of influenza virus hemagglutinin by subtype-specific and cross-reactive proliferative T cells: contribution of HA₁ and HA₂ polypeptide chains. *J. Immunol.* **134**, 616–622.
- Katz, J. M., Brown, L. E., French, R. A., and White, D. O. (1985b): Murine helper T lymphocyte response to influenza virus: recognition of hemagglutinin by subtype-specific and cross-reactive T cells clones. *Vaccine (Supplement)* **3**, 257–262.
- Kendal, A. P., and Cate, T. R. (1983): Increased sensitivity and reduced specificity of hemagglutination inhibition tests with ether-treated influenza B/Singapore/222/79. *J. clin. Microbiol.* **18**, 930–934.
- Kostolanský, F., Russ, G., Styk, B., and Mucha, V. (1988): Changes in the haemagglutinin at acidic pH detected by the monoclonal antibodies to glycopolypeptides HA₁ and HA₂ of influenza A virus haemagglutinin. *Acta virol.* **32**, in press.
- Koszinowski, U. H., Allen, H., Gething, M. -J., Waterfield, M. D., and Klenk, H.-D. (1980): Recognition of viral glycoproteins by influenza A-specific cross-reactive cytolytic T lymphocytes. *J. exp. Med.* **151**, 945–958.
- Krystal, M., Elliott, R. M., Benz, E. W., Young, J. F., and Palese, P. (1982): Evolution of

- influenza A and B viruses: Conservation of structural features in the haemagglutinin genes. *Proc. natn. Acad. Sci. USA*, **79**, 4800–4804.
- Kuo, Y. C., Oxford, J. S., and Schild, G. C. (1978): Immunological studies with the HA1 and HA2 polypeptides of influenza A virus haemagglutinin. *Exptl. Cell. Biol.* **46**, 338–354.
- Laemmli, U. K. (1970): Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature (Lond.)* **22**, 680–685.
- Lamb, J. R., Eckels, D. D., Lake, P., Woody, J. N., and Green, N. (1982): Human T-cell clones recognize chemically synthesized peptides of influenza haemagglutinin. *Nature (Lond.)* **300**, 66–68.
- Lu, B.-L., Webster, R. G., and Hinshaw, V. S. (1982): Failure to detect hemagglutination-inhibiting antibodies with intact avian influenza virions. *Infect. Immun.* **38**, 530–535.
- Poláková, K., Russ, G., and Styk, B. (1978): Antigenic glycopolypeptides HA₁ and HA₂ of influenza virus haemagglutinin. I. Gel filtration in 6 M guanidine hydrochloride. *Acta virol.* **22**, 362–370.
- Poláková, K., and Russ, G. (1983): Production and characterization of monoclonal antibodies against avian myeloblastosis virus. *Neoplasma* **30**, 625–635.
- Russ, G., Styk, B., and Poláková, K. (1978): Antigenic glycopolypeptides HA₁ and HA₂ of influenza virus haemagglutinin. II. Reactivity with rabbit antisera against intact virus and purified undissociated haemagglutinin. *Acta virol.* **22**, 371–382.
- Russ, G., Varečková, E., and Styk, B. (1974): Steric effects in the reaction of influenza virus neuraminidases with antibodies. *Acta virol.* **18**, 299–306.
- Russ, G., Kostolanský, F., Styk, B., Varečková, E., Soláriková, S., and Mucha, V. (1988): Use of monoclonal antibodies for topological mapping of antigenic sites of HA₁ and HA₂ subunits of influenza virus haemagglutinin. *Acta virol.* **32**, in press.
- Saitou, N., and Nei, M. (1986): Polymorphism and evolution of influenza A virus genes. *Mol. Biol. Evol.* **3**, 57–74.
- Schild, G. C., Oxford, J. S., and Virelizier, J. L. (1976): The immune response to influenza—Methods of analysis for antibodies and antigens. In R. F. Beers, Jr., and Bassett, E. G. (Eds): *The Role of Immunological Factors in Infectious, Allergic and Autoimmune Processes*, Raven Press, New York.
- Spiro, R. G. (1965): The carbohydrate units of thyroglobulin. *J. Biol. Chem.* **240**, 1603–1610.
- Styk, B., and Blaškovič, D. (1973): Immunodiffusion with animal influenza viruses and antibody. *Arch. exp. Vet. Med.* **27**, 1–19.
- Styk B., Russ, G., and Poláková, K. (1979): Antigenic glycopolypeptides HA₁ and HA₂ of influenza virus haemagglutinin. III. Reactivity with human convalescent sera. *Acta virol.* **23**, 1–8.
- Wabuke-Bunoti, M. A. N., and Fan, D. P. (1983): Isolation and characterization of a CNBr cleavage peptide of influenza viral haemagglutinin stimulatory for mouse cytolytic T lymphocytes. *J. Immunol.* **130**, 2386–2391.
- Ward, C. W. (1981): Structure of the influenza virus haemagglutinin. *Curr. Topics Microbiol. Immunol.* **94/95**, 1–74.
- Wiley, D. C., Wilson, I. A., and Skehel, J. J. (1981): Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. *Nature (Lond.)* **289**, 373–378.
- Wilson, I. A., Skehel, J. J., and Wiley D. C. (1981): Structure of the haemagglutinin membrane, glycoprotein of influenza virus at 3 Å resolution. *Nature (Lond.)* **289**, 366–373.

Explanation of Figures (Plates LV–LVIII)

- Fig. 1.** SDS-PAGE of immunoprecipitates of ¹²⁵I-BHA and anti-HA MoAb
Approx. 2 × 10⁶ cpm of ¹²⁵I-labelled BHA from A/Dunedin/4/73 (H3N2) virus (corresponding to about 20 ng of protein) was incubated with MoAb separately. Immunoprecipitates were analysed in SDS-PAGE (10 %) under reducing conditions with subsequent autoradiography. Lanes: 1. ¹²⁵I-BHA (total); 2. IVG6; 3. IIF4; 4. IB8; 5. IC8; 6. IB5; 7. IIC5; 8. IVA1; 9. IIB4; 10. IVE8 (anti-NP); 11. mouse anti-A/Dun. serum; 12. mouse preimmune serum. (Lanes 2–10.: MoAb.)
- Fig. 2.** SDS-PAGE of immunoprecipitates of ¹²⁵I-BHA and anti-HA MoAb
Experimental conditions were the same as described in Fig. 1.

Lanes: 1. ^{125}I -BHA (total); 2. IIE11 (anti-NA); 3. FC12; 4. BB8; 5. EB12; 6. IIB4; 7. FE1; 8. IB8; 9. IIF4; 10. IVG6; 11. mouse anti-A/Dun. serum; 12. mouse preimmune serum. (Lanes 2.—10.: MoAb.)

Fig. 3. Immunoblotting analysis of fine specificity of anti-HA MoAb.

Purified BHA originating from A/Dun. virus was separated to its HA₁ and HA₂ glycopolypeptide in SDS-PAGE under reducing conditions and glycopolypeptides were blotted electrophoretically onto nitrocellulose sheet. After incubation with MoAb separately, immunocomplexes were detected using anti-mouse Ig, conjugated to horseradish peroxidase.

Lanes: 1. mouse anti-A/Dun. serum; 2. Sp2/0 cells supernatant; 3. IB5; 4. IIC5; 5. IB8; 6. IC8; 7. IVA1; 8. IVG6; 9. IIB4; 10. IIF4; 11. BB8; 12. CB8; 13. CF2; 14. EF1; 15. EB12; 16. FC12; 17. FE1. (Lanes 3.—17.: MoAb.)

Fig. 4. Immunoblotting analysis of fine specificity of anti-HA MoAb.

Purified virus A/Bangkok/1/79 (H3N2) was separated to structural subunits in SDS-PAGE under reducing conditions and proteins were blotted electrophoretically onto nitrocellulose sheet. After incubation with monoclonal antibodies separately, immunocomplexes were detected using anti-mouse Ig conjugated to horseradish peroxidase.

Lanes: 1. mouse anti-MRC 11 serum; 2. mouse preimmune serum; 3. IVA1; 4. IVG6; 5. IVC4; 6. IIB4; 7. IIG3; 8. IIE5; 9. IIF5; 10. IIF4; 11. BB8; 12. CF2; 13. EB12; 14. FC12; 15. FE1; 16. CB8; 17. EF1. (Lanes 3.—17.: MoAb.)